{"id":65623,"date":"2025-03-14T00:01:19","date_gmt":"2025-03-14T00:01:19","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2025\/03\/14\/%e3%80%90c-s-group%e3%80%91-antcin-a-and-steroid-combination-shows-synergistic-potential-in-preliminary-study\/"},"modified":"2025-03-14T00:01:19","modified_gmt":"2025-03-14T00:01:19","slug":"%e3%80%90c-s-group%e3%80%91-antcin-a-and-steroid-combination-shows-synergistic-potential-in-preliminary-study","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/%e3%80%90c-s-group%e3%80%91-antcin-a-and-steroid-combination-shows-synergistic-potential-in-preliminary-study\/","title":{"rendered":"\u3010C.S Group\u3011: Antcin A and Steroid Combination Shows Synergistic Potential in Preliminary Study"},"content":{"rendered":"
\n

TAIPEI<\/span><\/span>, March 14, 2025<\/span><\/span> \/PRNewswire\/ —\u00a0Cordyceps Sunshine Biotech Holdings Co., Ltd. <\/b>\u3010<\/b>C.S Group<\/b>\u3011<\/b>, in collaboration with the Chinese Herbal Fungi Industry Research and Development Association (CHFIRDA)<\/b>, hosted the “Pharmacological Applications of Taiwanofungus Camphoratus in the Pet Market” Seminar<\/b> in Taipei<\/span>. During the event, \u3010<\/b>C.S Group<\/b>\u3011<\/b> officially announced its latest research findings, revealing that Antcin A<\/b>, a purified extract from Taiwanofungus camphoratus, demonstrates potential synergistic effects with traditional steroids<\/b>.<\/p>\n

The company is also exploring partnerships with premium pet food brands in China<\/span><\/b> and plans to introduce exclusively supplied Taiwanofungus camphoratus extracts<\/b> through its Greater China<\/span> distributor, Guangdong Baoquan Agricultural Biotechnology<\/b>, as part of its strategy to expand into the high-end pet food market.<\/p>\n

Accelerating Commercialization of Taiwanofungus Camphoratus-Based Pharmaceuticals<\/b><\/p>\n

Dr. Jia-Xin Huang<\/span><\/b>, a leading expert in Taiwanofungus camphoratus<\/b>, <\/b>emphasized that developing new biopharmaceuticals<\/b> traditionally requires extensive investment in animal and human trials, with no guarantee of success. However, Taiwanofungus camphoratus has already been extensively researched, providing a strong scientific foundation without needing to start from scratch.<\/p>\n

A key concern in previous discussions has been the long-term use of traditional steroids<\/b>,<\/b> which often leads to liver and kidney damage<\/b> as a side effect. Taiwanofungus camphoratus is known for its liver- and kidney-protective properties<\/b>, <\/b>prompting further studies into its potential to reduce the adverse effects of steroids without compromising efficacy<\/b>.<\/p>\n

To validate this hypothesis,\u00a0\u3010<\/b>C.S Group<\/b>\u3011<\/b>\u00a0conducted an experiment combining its proprietary TF-15 Taiwanofungus camphoratus extract with the steroid dexamethasone (DXMS) in lung cancer cell models. The study confirmed:<\/p>\n

    \n
  1. Genetic verification of TF-15 confirmed its authenticity \u3010<\/b>C.S Group<\/b>\u3011<\/b>as a Taiwanofungus camphoratus strain.<\/li>\n
  2. TF-15 exhibits comparable potency to wood-cultivated Taiwanofungus camphoratus fruiting bodies.<\/li>\n
  3. A high concentration of Antcin A was successfully extracted through a multi-stage purification process.<\/li>\n
  4. The combination of Antcin A and dexamethasone showed potential synergistic effects in reducing and reversing cancer cell growth.<\/li>\n<\/ol>\n

    Recognizing the regulatory and commercialization advantages of veterinary applications, \u3010<\/b>C.S Group<\/b>\u3011<\/b>\u00a0is prioritizing preclinical trials for pet medicine. The strategy includes:<\/p>\n